Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Search
Saturday, October 5, 2024
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Read Magazine’s Weekly News Roundup With Anduril, CropX, Alogent, Honeywell, Vertiv,…
Spectral AI Advances Wound Measurement Tech
Extensiv Appoints Aaron Stead as CEO
Amyris Partners with BioMaP for Critical Medicines
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Home
Tags
OSE Immunotherapeutics
OSE Immunotherapeutics
Biotechnology
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
News Desk
-
July 4, 2024
Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company, announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology program into...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
Read Magazine’s Weekly News Roundup With Anduril, CropX, Alogent, Honeywell, Vertiv, Lavu, And More!
Spectral AI Advances Wound Measurement Tech
Extensiv Appoints Aaron Stead as CEO
Load more
